Double Filtration Plasmapheresis Combined With Chemotherapy
NCT ID: NCT04836871
Last Updated: 2023-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
20 participants
INTERVENTIONAL
2021-05-15
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Plasma-free Replacement in Patients With Multiple Myeloma
NCT05251896
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
NCT01772719
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
NCT06203145
Autologous Transplant for Multiple Myeloma
NCT00177047
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
NCT05378971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Double filtration plasmapheresis (DFPP) combined with chemotherapy
DFPP combined with chemotherapy
Double filtration plasmapheresis combined with chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DFPP combined with chemotherapy
Double filtration plasmapheresis combined with chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with stable condition after conventional treatment
* Patients with renal insufficiency or abnormal M protein
* Patients over 18 years of age
* Liver function: blood bilirubin ≤ 35μmol/L, enzymes aspartate transaminase (AST)/aka alanine aminotransferase (ALT) is less than 2 times the upper limit of normal
* Normal heart function
* Physical condition score 0-2 level (ECOG score)
* Obtain an informed consent form signed by the patient or family member
Exclusion Criteria
* Severe heart disease, including myocardial infarction and cardiac insufficiency.
* Suffering from other organ malignancies
* Active tuberculosis patients and HIV-positive patients
* At the same time suffering from other blood system diseases
* Pregnant or lactating women
* Able to understand or follow the research plan
* Past history of intolerance or allergy to similar drugs
* Patients under 18 years of age
* Participating in other clinical researchers at the same time
* There are any other circumstances that hinder the progress of the research
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fuling Zhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fuling Zhou
Head, Division of Hematology; Professor of Hematology; Doctoral advisor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.